CRISPR Therapeutics
CRSP
CRSP
410 hedge funds and large institutions have $2.79B invested in CRISPR Therapeutics in 2024 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 131 increasing their positions, 127 reducing their positions, and 73 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
410
Holders Change
-34
Holders Change %
-7.66%
% of All Funds
5.93%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
44
Increased
131
Reduced
127
Closed
73
Calls
$68.2M
Puts
$103M
Net Calls
-$34.8M
Net Calls Change
-$42.8M
Top Buyers
| 1 |
BBA
Baker Bros. Advisors
New York
|
$39.6M |
| 2 |
State Street
Boston,
Massachusetts
|
$141M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
$29.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
$24.4M |
| 5 |
UBS Group
Zurich,
Switzerland
|
$31.6M |
